Tuesday, 13 May 2025
  
Login

Australia's most trusted
source of pharma news

Tuesday, 13 May 2025
News

Lilly beats rival in epic showdown

 Posted 12 May 2025 PM

Lilly has claimed victory in one of the most hotly contested markets in pharma with a head-to-head study demonstrating its obesity drug Mounjaro trounced rival Novo Nordisk's Wegovy for weight loss.

The Phase 3b SURMOUNT-5 trial pitted Mounjaro against Wegovy in adults living with obesity or overweight with at least one weight-related medical problem and without diabetes. Detailed results were published today in the New England Journal of Medicine today.

To see the whole article, please login

Popular

PBAC Agenda blows out to 59
Lilly beats rival in epic showdown
Splashing millions on meetings
Butler returns in supersized role
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (12)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (4)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home